Assessment of Antiphospholipid Antibodies, CD4 

Count and Some Haematological Parameters in HIV 

Patients attending a Tertiary Health Institution in 

South-Western Nigeria by Olayanju, Ayodeji OluSola et al.
 _____________________________________________________________________________________________________ 
 
*Corresponding author: E-mail: enitans@babcock.edu.ng; 
 
 
 
International Blood Research & Reviews 
 
8(2): 1-14, 2018; Article no.IBRR.41710 
ISSN: 2321–7219 
 
 
 
 
Assessment of Antiphospholipid Antibodies, CD4 
Count and Some Haematological Parameters in HIV 
Patients attending a Tertiary Health Institution in 
South-Western Nigeria 
 
Olayanju Ayodeji OluSola1, Afolabi Temitope2, Ezigbo, Eyiuche Doris3,  
Enitan Seyi Samson2* and Oluwatayo Beatrice Olatundun4 
   
1Department of Medical Laboratory Science, Afe Babalola University, Ado-Ekiti, Ekiti State, Nigeria. 
2Department of Medical Laboratory Science, Babcock University, Ilishan-Remo, Ogun State, Nigeria. 
3Department of Medical Laboratory Science, University of Nigeria, Nsukka, EnuguState, Nigeria. 
4Department of Haematology, Federal College of Veterinary & Medical Laboratory Technology, Vom, 
Plateau State, Nigeria. 
 
Authors’ contributions  
 
This work was carried out in collaboration between all authors. Authors OAOS and AT designed the 
study, performed the statistical analysis, wrote the protocol and wrote the first draft of the manuscript. 
Authors EED and ESS managed the analyses of the study. Author OBO managed the literature 
searches. All authors read and approved the final manuscript 
 
Article Information 
 
DOI: 10.9734/IBRR/2018/41710 
Editor(s): 
(1) Mehmet Sonmez, Professor, Department of Haematology, School of Medicine,  Karadeniz Technical University,  
Turkey.  
Reviewers: 
(1) Dorathy Chioma , University of Calabar, Nigeria. 
(2) Tabe Franklin Nyenty, University of Ngaoundere, Cameroon. 
(3) V. O. Mabayoje, Ladoke Akintola University of Technology, Nigeria. 
Complete Peer review History: http://www.sciencedomain.org/review-history/24876 
 
 
 
Received 20th March 2018 
Accepted 26th May 2018 
Published 30th May 2018 
 
 
ABSTRACT 
 
Background: Antiphospholipid antibodies (aPLs) are the serological markers used in the diagnosis 
of the antiphospholipid syndrome (APS). HIV infection has been associated with an elevated aPls 
level, but its link to the APS with clinical thrombosis is still been investigated. This study is designed 
to determine and correlate serum level of antiphospholipid antibodies with CD4 count and some 
haematological parameters of HIV seropositive subjects in comparison to those of healthy controls 
Original Research Article 
 
 
 
 
Olayanju et al.; IBRR, 8(2): 1-14, 2018; Article no.IBRR.41710 
 
 
 
2 
 
and also to compare these parameters between antiretroviral therapy (ART) naïve and treated 
patients. 
Methodology: A cohort of 110 patients which consist of 90 HIV positive Patients (22 males and 68 
females) and 20 HIV negative patients (10 males and 10 females) which serve as control attending 
Babcock University Teaching Hospital (BUTH) Ilishan-Remo, Ogun State, Nigeria were recruited for 
the cross-sectional study. HIV antibodies were detected using 3 rapid diagnostic kits (Determine, 
Unigold and Stat Pak). CD4+ cells were counted using Partec® Cyflow Counter (Germany). The Full 
Blood Count was analyzed using the Sysmex® Automated Haematology Analyzer (Kobe-Japan). 
Antiphospholipid antibodies (aPLs) were assayed using the Human Anti-Phospholipid Screen 
IgG/IgM ELISA kit (Alpha Diagnostic International, Texas, USA).                             
Results: The present study showed that the mean serum antiphospholipid antibody level was 
significantly (P<0.001) higher in HIV positive Patients (11.83±7.36u/ml) compared to the control 
group (7.30±3.95u/ml). While on one hand, there was a strong positive correlation between serum 
aPLs level and PLT (r= 0.044), MCHC (r= 0.084) and LYM (r= 0.105) in HIV infection; on the other 
hand, there was a strong negative correlation with CD4 count (r= -0.094), PCV (r= -0.099), Hb (r= -
0.072), RBC (r= -0.003), WBC (r= -0.063), MNO (r= -0.213), GRA (r= -0.003), MCV (r= -0.023) and 
MCH (r= -0.005). Also, there was no significant differences (P>0.05) between the aPLs level of HIV 
group on ART (11.44±7.74 u/ml) and those not on ART (12.00±7.24 u/ml). Some haematological 
parameters like PLT, PCV, Hb, RBC and red cell indices of the HIV group on ART did not differ 
significantly from those not on ART. However, the CD4 count (638.89±119.56 cell/μL), WBC 
(5.38±1.49X103/μL), LYM (51.43±7.99%) and GRA (46.30±10.18%) of the HIV group on ART were 
significant higher than those not on ART (465.30±145.92 cell/μL, 4.55±1.57X103/μL, 42.23±10.96% 
and 39.10±7.81%, respectively).                                                    
Conclusion: Significant elevated aPLs level is present in HIV infection; however, the information 
obtained is not sufficient to indicate the occurrence of anti-phospholipid syndrome in HIV infection. 
There was no strong relationship between aPLs level and indicators of immunohaematological 
abnormalities in HIV infection. This finding is plausible and would therefore require further 
investigation. 
 
 
Keywords: Anti-phospholipid antibodies; anti-phospholipid syndrome; HIV; CD4 cell count; 
haematological parameters. 
 
1. INTRODUCTION 
 
Antiphospholipid antibodies (aPLs) are a 
heterogeneous group of autoantibodies that can 
bind directly to phospholipids, thus allowing them 
to exert an influence on protein cofactors or 
complexes containing phospholipids. They are 
used as the serological markers in the diagnosis 
of the antiphospholipid syndrome [1]. 
 
Anti-phospholipid syndrome (APS) on the other 
hand, is an acquired thrombophilic disorder in 
which autoantibodies are produced to a variety of 
phospholipids and phospholipid binding proteins 
[2]. It has also be defined as a multisystem 
autoimmune disease, as well as hypercoagulable 
state caused by the presence of antiphospholipid 
antibodies (aPLs) namely: lupus anticoagulant 
(LA), anticardiolipin antibodies (aCLs), or anti-β2 
glycoprotein-1 (β2GP1) antibodies which directly 
react against phospholipids and phospholipid 
binding proteins including cardiolipin, 
phosphatidylserine, phosphatidylinositol, 
phosphatidylethanolamine, phosphatidylglycerol, 
and phosphatidylcholine resulting in the 
occurrence of venous and arterial thrombosis, 
recurrent fetal loss, thrombocytopenia, and other 
clinical manifestations in the presence of 
persistent circulating antiphospholipid antibodies 
[3-5]. 
 
According to Wilson et al. [6], a patient with 
‘‘definite’’ APS must have persistent high-titer 
antiphospholipid antibodies (aPLs) associated 
with a history of arterial or venous thrombosis (or 
both), or recurrent pregnancy morbidity. 
Laboratory criteria are well defined and require 
aCL IgG or IgM or lupus anticoagulant in high 
titers (>40 IgG phospholipid units [GPL]                         
or IgM phospholipid units [MPL] or >99th 
percentile), confirmed on repeat testing 12 weeks 
later). The 2006 International Criteria have 
included IgG and IgM antibodies to β2GP1, which 
are also highly predictive of risk for thrombosis. 
Patients may be found to have not only aCL or 
lupus anticoagulant but also other aPLs or 
combinations which are not included in the 
criteria [7]. 
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The primary mechanism behind the 
hypercoagulable state has been thought to be 
activation of endothelial cells, monocytes and 
platelets by antiphospholipid antibodies [8]. This 
leads to increased expression of adhesion 
molecules on endothelial cells and upregulation 
of tissue factor. Activated platelets also 
synthesize thromboxane A2 altering the 
prostacyclin-thromboxane balance to favour 
thrombosis. In addition, aPLs may also impair 
fibrinolysis and interefere with the 
thrombomodulin-protein C-protein S pathway [9]. 
Haematological manifestations of APS include: 
thrombocytopenia, autoimmune haemolytic 
anaemia (AIHA), bone marrow necrosis (BMN) 
and thrombotic microangiopathy among several 
others [10,11].      
 
The syndrome has been classified into two main 
classes: primary and secondary. In the former, 
anti-phospholipid syndrome occurs in the 
absence of any known autoimmune disorder as 
seen in patients having neither clinical nor 
laboratory evidence of another definable 
condition. In the latter, anti-phospholipid 
syndrome is seen in conjunction with other 
autoimmune diseases such as systemic lupus 
erythematosus. In rare cases, anti-phospholipid 
syndrome leads to rapid organ failure due to 
generalized thrombosis and a high risk of death; 
this is termed as “catastrophic antiphospholipid 
syndrome” (CAPS).  
   
Precise cause of primary anti-phospholipid 
syndrome is unknown. However, some factors 
are associated with developing anti-phospholipid 
antibodies though not necessarily the syndrome 
as noted by previous Researchers [12-16]. 
These include: Infections (e.g HIV infection, 
Hepatitis C Virus infection, Syphilis and malaria, 
with a higher incidence of positivity of anti-
phospholipid antibodies), medications 
(consumption of certain drugs, such as 
hydralazine, quinidine, phenytoin, and antibiotics 
such as amoxicillin may lead to an increased risk 
of APS) and genetic predispositions (although 
the disorder is not considered hereditary, 
research indicates that relatives of people with 
anti-phospholipid syndrome are more likely to 
have the antibodies). 
 
An association between antiphospholipid 
antibodies (aPLs) and infectious agents in 
particular has been reported in several 
epidemiologic and experimental studies [16]. The 
connection between infections and aPLs has 
been supported by some indirect evidences, 
such as the seasonal distribution of aPLs [17] 
and high frequency of aCLs in healthy children 
who frequently suffer from a wide range of 
common viral infections [18]. Infection-induced 
aPLs have been traditionally regarded as 
transient and were generally not associated with 
clinical features of antiphospholipid syndrome. 
Several reports demonstrated that some patients 
can produce pathogenic antibodies in response 
to infection [15]. 
 
Viral agents most frequently associated with 
antiphospholipid syndrome include: HIV, 
Parvovirus B19, Cytomegalovirus, Varicella-
Zoster Virus, Hepatitis C Virus, Epstein-Barr 
Virus, HTLV-1, Adenovirus, Influenza Virus, 
Mumps Virus and Rubella Virus [15,19,20]. 
 
HIV is a pandemic and has remained a public 
health concern for many decades. HIV infection, 
though associated with many opportunistic 
infections and neoplasms, it is further 
complicated with marked depletion of the CD4 
Cells and haematological abnormalities [21,22]. It 
has also been associated with an increased 
prevalence of anti-phospholipid antibodies, but 
its link to the anti-phospholipid syndrome with 
clinical thrombosis remains focus of research 
[23]. A 2-10 fold increased incidence of venous 
thromboembolism (VTE) has been reported 
among HIV infected persons compared with the 
HIV-negative population of the same age. While 
most abnormal coagulation factors/markers 
improve after starting HAART, the disturbances 
fail to normalize completely in some [24]. HIV 
patients have also been reported to have a 
higher incidence of the lupus anticoagulant and 
antiphospholipid antibodies than the general 
population, which may contribute to a 
hypercoagulable state. HIV-infected patients may 
produce aPLs, in particular of IgM isotype, but 
full-blown clinical features of APS are distinctly 
uncommon [25]. 
 
Furthermore, anti-phospholipid syndrome can be 
diagnosed by lupus anticoagulant assays [3] and 
Enyzme linked immunoabsorbent assays [7]. The 
presence of antiphospholipid antibodies (aPLs) 
has been detected in approximately 5–20% of 
the healthy population. The prevalence increases 
with age, especially in elderly individuals with 
chronic disease [26] and is more common in 
women than men in about a 5:1 ratio [27]. The 
risk of thrombosis in patients with APS is 
estimated to range from 0.5% to 30% [28]. 
Anticardiolipin antibodies (ACAs) have been 
reported in HIV infected patients with a 
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prevalence ranging from 7% to 94% [29,30]. 
Antiphospholipid antibodies have also been 
detected in patients with acute and chronic 
infections and malignant diseases [5,31,32].  
 
Abuaf [33], investigated the prevalence of aPLs 
in HIV infection. Anticardiolipn antibodies (aCLs) 
were reported to be present in 0-94%, anti-β2-
glycoprotein-1 (anti-β2-GP1) in 4-47%, anti-
prothrombin (aPT) in 2-12% of patients with 
lupus anticoagulant (LA) found in 0-53.5%. 
Similarly, Loizou et al. [34], studied the 
prevalence of aPLs in 100 black South African 
HIV positive patients. Their results show that 
there was a low prevalence of anti-β2-GP1 (6%), 
all exclusively belonging to the IgA isotype, as 
well as aCL (7%), which were mainly positive for 
IgG. A prevalence of 43% (mainly IgG) aPT was 
found showing that the pattern of aPLs in black 
South Africans differs from that found in 
caucasians [34].  
   
Even though anti-phospholipid syndrome has 
been reported to be associated with HIV 
infections, the evaluation of markers predictive 
for this disease is not done routinely. This is 
worrisome because the development of 
antiphospholipid antibodies in HIV infected 
individuals can further worsen the deteriorating 
immune responsiveness. Therefore, the 
knowledge of the presence of these antibodies 
will aid appropriate clinical intervention. To the 
best of our knowledge, no work has been done 
on the haematological correlate of anti-
phospholipid syndrome in HIV infected Patients 
attending Babcock University Teaching Hospital 
(BUTH) Ilishan-Remo, Ogun State, Nigeria. Lack 
of data in this regard, necessitates this research. 
The aim of this study is therefore to determine 
and correlate serum level of antiphospholipid 
antibodies with CD4 count and some 
haematological parameters of HIV seropositive 
subjects in comparison to those of healthy 
controls and also to compare these parameters 
between antiretroviral therapy (ART) naïve and 
treated patients. 
 
2. METHODOLOGY 
 
2.1 Study Area 
 
The study was carried out at the HIV Clinic, 
Babcock University Teaching Hospital (BUTH) 
Ilishan-Remo, Ikenne Local Government Area, 
Ogun State, South-Western region of Nigeria, 
coordinates: 6O 52’ N3O 43O E. 
  
2.2 Study Duration 
 
This study was carried out between January and 
April, 2017. 
 
2.3 Sample Size Calculation 
 
The minimum sample size (n) required for                  
the study was estimated using the                         
population proportion formula described by Naing 
et al. [35]: 
 
 Z2 X P (1-P)     
         d2 
Where: 
 
N = minimum sample size 
Z = confidence interval (1.96) 
P = 5.5%, prevalence of sero-positivity of HIV 
infection from previous study [36]. 
d = desired level of significance (0.05) 
 
N = 1.962 X 0.060 (1-0.055) = 79 
                      (0.05)2 
 
The minimum sample size required (N) = 79 
 
However, to make our work more robust, we 
decided to screen a total of 90 test Subjects and 
20 control Subjects. 
 
2.4 Subjects 
 
Ninety (90) HIV Patients attending HIV Clinic, 
Babcock University Teaching Hospital (BUTH) 
Ilishan-Remo, Ogun State were recruited as Test 
Subjects, while 20 apparently healthy HIV 
negative individuals were used as Controls. 
 
2.5 Eligibility of Subject 
 
2.5.1 Inclusion criteria 
 
Consenting HIV positive Patients without any 
other immunosuppressive disease/condition 
except HIV/AIDS attending HIV Clinic,                     
Babcock University Teaching Hospital (BUTH) 
Ilishan-Remo, Ogun State were recruited for the 
study. 
 
2.5.2 Exclusion criteria 
 
Non-consenting HIV positive Patients, as well                          
as HIV positive Patients with other immune              
suppressive disease/condition were excluded 
from the study. 
 
N =
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2.6 Study Design 
 
This is a cross-sectional hospital-based study. 
Pre-test counselling was instituted in which the 
purpose, benefit and procedures of the study 
were explained to the participants. A brief 
structured questionnaire was used to obtain 
demographic information from consenting 
subjects. Interpreter was provided for translation 
in local dialect where necessary. Informed 
consent was obtained from each patient and all 
participants were requested to voluntarily sign 
the consent forms in their own handwriting. The 
study groups were stratified by sex, level of 
education, occupation and marital status.                  
All data were kept confidential in accordance with 
World Medical Association Declaration of 
Helsinki [37]. 
 
2.7 Sample Collection and Handling 
 
Using standard aseptic procedures, ten (10) 
milliliters of blood was collected from each 
participant and 5 ml was dispensed into a 
container having 0.08 ml of ethylene diamine 
tetra-acetic acid (EDTA) and the remaining 5 ml 
was placed in a plain container, allowed to clot 
and separated by centrifugation at room 
temperature. Sera were immediately assayed. 
Caution was also taken not to use highly lipemic 
or hemolyzed or heat inactivated samples 
throughout the study. The sera obtained were 
used for the detection of HIV and anti-
Phospholipid antibodies, while the anti-
coagulated blood was used for the determination 
of CD4 count and full blood count using 
previously described methods. 
 
2.8 Laboratory Analysis   
 
2.8.1 HIV detection   
 
HIV detection was carried out using the current 
National algorithm for HIV sero-diagnosis. This 
involved the use of 3 rapid diagnostic kits, 
following their manufacturer’s instructions. 
Briefly, each patient’s serum was screened for 
the presence of HIV antibodies using Determine 
(Abbott Laboratories, Tokyo, Japan) and Unigold 
HIV (Trinity Biotech Plc Bray, Co. Wicklow, 
Ireland). When both kits showed positivity, the 
patient was regarded as positive for HIV infection 
and vice versa. However, when test results were 
discordant, a third kit, which is the Tie breaker, 
1/2 Stat Pak (Chembio Diagnostic Systems, New 
York, USA) was used. The HIV serostatus of the 
patient was taken as the result of either of the 
first two kits that agree with that of the third kit 
[22]. 
 
2.8.2 CD4+ cell count evaluation   
 
CD4+ cell count was evaluated using Partec® 
Cyflow Counter (Germany), as described by PCC 
[38]. The Cyflow Counter was operated as 
instructed in the user’s operational manual. 
 
2.8.3 Haematological Parameters Analysis 
 
Full Blood Count was analyzed using the 
Sysmex® Automated Haematology Analyzer KX-
21N, Sysmex Corporation, (Kobe-Japan) as 
described by Samuel et al. [38]. 
 
2.8.4 Antiphospholipid antibodies Assay 
 
The Antiphospholipid antibodies (aPLs) were 
assayed by Immunometric Enzyme 
Immunoassay using the Human Anti-
Phospholipid Screen IgG/IgM ELISA kit supplied 
by Alpha Diagnostic International, Texas, USA as 
described by Banzato et al. [39]. The                      
ELISA plate washer and ELISA reader were 
operated as instructed in the user’s operational 
manual. 
 
2.9 Statistical Analysis 
 
Data generated are presented as mean±SEM 
using tables and analyzed using Statistical 
Packages for Social Sciences – Version 18.0 
(SPSS-18.0). Student’s t-test was used to 
compare two variables and one-way-analysis of 
variance (ANOVA) for more than two variables. P 
values<0.05 were considered statistically 
significant. Data were also subjected to Pearson 
correlation analysis using Graphpad INSTAT® 
Software Package to determine the relationship 
between aPLs and CD4 Cell count, as well as 
haematological parameters. An association was 
established between two variables when an OR 
value ≥1.00 was obtained [40]. 
 
3. RESULTS AND DISCUSSION 
 
3.1 Results  
 
The socio-demographic characteristics of the test 
subjects are presented in Table 1. Sixty-eight 
(68) females and twenty- two (22) males 
participated in this study. The level of education 
with the highest percentage was Bachelor’s 
degree with 63.3%. Most of the participants were 
self-employed (54.4%) and married (53.3%). The 
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risk factors of the test subjects and their 
responses towards routine clinics and 
medications are presented in Table 2. 63 (70%) 
out of the 90 HIV Subjects are on antiretroviral 
therapy while the remaining 27 (30%) were not. 
However, they all attend routine clinic. Also 70% 
of these Patients take herbs while 30% do not. 
Table 3 shows the comparison of Mean±SEM 
Age, aPLs, CD4 Count and Haematological 
parameters of HIV Positive and control: CD4 
count (0.001), PCV (0.001), WBC (0.001), MCV 
(0.012), MCH (0.001), MCHC (0.001) and aPLs 
(0.088). All have a P-value that is statistically 
significant (P<0.05). While the p-value for Age, 
Hb, RBC, PLT, LYM, MNO, GRA are greater 
than 0.05 (P>0.05) which were considered 
statistically not significant. The comparison of 
mean±SEM aPLs, CD4 count and 
haematological parameters of HIV Positive 
Participants on ART and those not on ART is
 
Table 1. Socio-demographic Characteristics of the HIV positive participants 
 
Characteristics Frequency Percentage (%) 
GENDER   
Male   22 24.4 
Female  68 75.6 
Total     90 100 
LEVEL OF EDUCATION   
Primary 1 1.1 
Secondary 14 15.6 
Graduate 57 63.3 
Postgraduate 18 20.0 
Total 90 100 
OCCUPATION   
Student 2 2.2 
Self Employed 50 55.1 
Civil Servants 38 42.7 
Total 90 100 
MARITAL STATUS   
Single 26 28.9 
Married 48 53.3 
Divorced 6 6.7 
Widow 8 8.9 
Widower 2 2.2 
Total 90 100 
 
 
 
Fig. 1. Scatter Plot showing relationship between aPL and CD4+ Cells. There is a negative 
correlation between the levels of aPl and CD4+ Cells (r= -0.094) 
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Table 2. Risk factors, routine clinic and medication of the HIV Positive Participants 
 
Risk factors Frequency Percentage (%) 
SMOKING   
No 90 100 
Yes 0 0 
Total     90 100 
DRINK ALCOHOL   
No 90 100 
Yes 0 0 
Total     90 100 
ON ROUTINE CLINIC   
No 0 0 
Yes 90 100 
Total     90 100 
ON ART   
No 27 30 
Yes 63 70 
Total 90 100 
OTHER MEDICATION   
No 90 100 
Yes 0 0 
Total     90 100 
HERBAL REMEDIES   
No 27 30 
Yes 63 70 
Total     90 100 
 
Table 3. Mean±SEM Age, aPLs, CD4 Count and Haematological parameters of HIV Positive and 
control 
 
Parameters HIV Positive (N=90) Control (N=20) T-Value P-Value 
Age (Yrs) 42.47±10.35 36.65±13.80 1.777 0.088 
aPLs (u/ml) 11.83±7.36 7.30±3.95 3.858 0.001* 
CD4 Count (cell/μL) 607.38±276.67 994.60±293.32 -5.395 0.001* 
PCV (%) 38.69±7.01 46.19± 5.67 -5.108 0.001* 
Hb (g/dl) 12.17± 1.97 14.67±1.77 -1.118 0.272 
RBC (X106/μL) 4.16± 0.86 4.26±0.72 -0.563 0.577 
PLT (X103/μL) 245.49±98.88 253.75±71.76 -0.432 0.668 
WBC (X103/μL) 4.80±1.59 7.36±0.97 -5.710 0.001* 
LYM# (%) 44.99±10.97 45.44±12.50 -0.150 0.882 
MNO# (%) 10.88±5.77 11.31±3.78 -0.413 0.682 
GRA# (%) 44.14±10.05 43.50±15.00 0.181 0.858 
MCV (fl) 78.35±6.22 94.52±13.52 -2.601 0.012* 
MCH (Pg)  24.46±1.92 29.77±4.88 -8.026 0.001* 
MCHC (g/dl) 27.95±2.60 31.56±0.90 -6.140 0.001* 
Keys: aPLs = antiphospholipids antibodies, CD4 = cluster of differentiation 4, PCV = Packed Cell Volume, Hb = 
Haemoglobin concentration, RBC = Red Blood Cell Count, WBC = White Blood Cell Count, PLT = Platelet count, 
MCV = Mean Cell Volume, MCH = Mean Cell Haemoglobin, MCHC = Mean Cell Haemoglobin Concentration, 
LYM# = Absolute Lymphocytes count, GRA# = Absolute Granulocytes Count. Test values differ significantly from 
control at P<0.05 
 
shown in Table 4. CD4 count (0.001), WBC 
(0.021), LYM (0.001) and GRA (0.001) have a P-
value that is statistically significant (P<0.05), 
while other haematological parameters have P-
value greater than 0.05 (P>0.05) which were 
considered statistically not significant. The 
relationship between the level of antiphospholipid 
antibodies and CD4 count and other 
haematological parameters are represented 
using scatter plot graphs (Figs. 1-12). There was 
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a strong positive correlation between serum 
antiphospholipid antibodies (aPls) level and PLT 
(0.044), MCHC (0.084) and LYM (0.105); on the 
other hand, there was a strong negative 
correlation with CD4 COUNT (-0.094), PCV (-
0.099), Hb (-0.072), RBC (-0.003), WBC (-0.063), 
MNO (-0.213), GRA (-0.003), MCV (-0.023) and 
MCH (-0.005). 
 
Table 4. Mean±SEM aPL, CD4 Count and some Haematological parameters of HIV Positive 
ART treated and naïve Patients  
 
Parameters On ART (N=63) Not on ART (N=27) T-Value P-Value 
aPLs (u/ml) 11.44±7.74 12.00±7.24 0.318 0.752 
CD4 Count (cell/μL) 638.89±119.56 465.30±145.92 10.277 0.001* 
PCV (%) 38.62±7.74 36.87±5.03 0.180 0.859 
Hb (g/dl) 12.16±2.14 11.19±1.57 0.069 0.945 
RBC (X106/μL) 4.17±0.91 4.13±0.76 0.181 0.857 
PLT (X103/μL) 268.64±91.17 231.48±95.18 0.915 0.366 
WBC (X103/μL) 5.38±1.49 4.55±1.57 2.375 0.021* 
LYM (%) 51.43±7.99 42.23±10.96 1.841 0.001* 
MNO (%) 11.48±6.36 9.48±3.81 0.69 0.069 
GRA (%) 46.30±10.18 39.10±7.81 3.644 0.001* 
MCV (fl) 79.78±14.05 75.98±13.35 0.563 0.567 
MCH (Pg)  25.79±4.62 24.72±5.24 0.057 0.955 
MCHC (g/dl) 28.65±0.92 27.35±0.83 1.507 0.138 
Keys: aPLs = antiphospholipids antibodies, CD4 = cluster of differentiation 4, PCV = Packed Cell Volume, Hb = 
Haemoglobin concentration, RBC = Red Blood Cell Count, WBC = White Blood Cell Count, PLT = Platelet count, 
MCV = Mean Cell Volume, MCH = Mean Cell Haemoglobin, MCHC = Mean Cell Haemoglobin Concentration, 
LYM# = Absolute Lymphocytes count, GRA# = Absolute Granulocytes Count. Test values differ significantly from 
control at P<0.05 
 
 
 
Fig. 2. Scatter Plot showing relationship 
between aPL and PCV. There is a negative 
correlation between the levels of aPl and PCV 
(r= -0.099) 
 
3.2 Discussion 
 
The present study was designed to determine 
and correlate serum level of antiphospholipid 
antibodies with CD4 count and some 
haematological parameters of HIV seropositive 
subjects in comparison to those of healthy 
controls and also to compare these parameters 
between antiretroviral therapy (ART) naïve and 
treated patients. Out of the 90 HIV positive 
Participants examined, 68 (75.6%) were females 
while 22 (24.4%) were males. This does not 
agree with the work of Abdollahi and Morteza 
[41], who reported no significant differences in 
the male-to-female ratio. 
 
 
 
Fig. 3. Scatter Plot showing relationship 
between aPL and Hb. There is a negative 
correlation between the levels of aPl and Hb 
(r= -0.097) 
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Fig. 10. Scatter Plot showing relationship 
between aPL and LYM. There is a positive 
correlation between the levels of aPl and LYM 
(r= 0.105) 
 
 
 
Fig. 11. Scatter Plot showing relationship 
between aPL and MID. There is a negative 
correlation between the levels of aPl and 
MNO (r= -0.213) 
 
 
 
Fig. 12. Scatter Plot showing relationship 
between aPL and GRA. There is a weak 
negative correlation between the levels of aPl 
and GRA (r= -0.003) 
 
The result of the present study showed that the 
mean serum antiphospholipid antibodies level 
was significantly (P<0.001) higher in HIV positive 
Patients (11.83±7.36 u/ml) compared to the 
control group (7.30±3.95 u/ml). This agrees with 
the work of Soto-vega et al. [1] and Abdollahi and 
Morteza [41], who both reported similar findings 
among HIV-positive patients compared to the 
healthy controls. It also agrees with the work of 
Abdel-Wahab et al. [15], who reported that viral 
infections like HIV can increase the risk of 
developing elevated aPLs and associated 
thromboembolic events. Detection of                         
aPLs in the controls agrees with previous reports 
that aPLs is present in apparently healthy 
population. While a higher mean serum aPLs in 
HIV cases confirms earlier claims that HIV 
infection is not unconnected with elevated aPLs 
levels. 
 
The present study further revealed that there was 
no significant correlation between levels of 
antiphospholipid antibody and CD4 Cell Count, 
as well as some haematological parameters in 
HIV patients. This agrees with the report of 
Palomo et al. [42], who observed no correlation 
between the presence of aPLs and                         
reduced platelet count (thrombocytopenia) in 
Chilean HIV-infected patients and Soto-                         
vega et al. [1], who also reported no correlations 
between antiphospholipid antibody titers and 
specific clinical manifestations in HIV positive 
patients. 
 
Furthermore, the Total White Blood Cell Count 
(4.80±1.59 X103/μL) and CD4 count 
(607.38±276.67cell/μL) of the HIV positive group 
were found to be significantly lower (P<0.001) 
than of the healthy controls (7.36±0.97 X103/μL, 
994.60±293.32 cell/μL, respectively). This is in 
agreement with the work of Abdollahi and 
Morteza [41], who obtained similar results among 
58 HIV-infected patients examined. White blood 
cell count is used to monitor treatment which can 
cause leucopenia, investigate HIV/AIDS, 
infections and unexplained fever. Leucopenia is 
one of the most common complications of HIV 
and may be broadly classified as being due 
either to a bone marrow production defect or to 
increased peripheral loss or destruction of blood 
cells. The causes for leucopenia in HIV infection 
are probably due to destruction of white cells by 
the HIV, as well as perturbed bone marrow 
cytokine homeostasis [43]. 
 
An autoimmune mechanism involving 
antigranulocyte antibodies and impaired 
granulopoiesis and any infiltrative process 
involving the bone marrow (infection, 
malignancy) has also been postulated [44]. HIV 
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is cytotoxic to T-helper lymphocytes, which in 
turn leads to dysregulation of B cells and altered 
release of cytokines. HIV-infected T cells directly 
suppress growth of bone marrow progenitors, 
thus suppressing haemopoiesis. CD4, the cell-
surface receptor target of HIV, is carried by T-
helper lymphocytes, monocytes and 
microvascular endothelial cells which are 
prevalent in marrow. The infection of monocytes 
in the marrow further alters release of cytokines, 
which indirectly suppress the capacity for 
haemopoietic progenitor cells to adequately 
respond to peripheral leucopenia [9,45,46]. 
 
Still, the Hb levels of the HIV patients (12.17± 
1.97 g/dl) in this study, were not significantly 
different (P>0.05) from that of the healthy 
controls (14.67±1.77 g/dl). This is in accordance 
with the work of Abdollahi and Morteza [41]. The 
clinical values of measuring haemoglobin 
concentration include: to screen blood donor 
prior to blood donation, detect anemia and it 
severity and to monitor an anaemic patient’s 
response to treatment. It is also useful in 
monitoring patients with HIV disease receiving 
drugs such as AZT. 
 
The mean PCV value of the HIV positive Patients 
(38.69±7.01%) were found to be significantly 
(P<0.001) lower than the healthy controls 
(46.19± 5.67%). This partly support the results of 
previous study by Osime et al. [47], who reported 
a non-significant (P>0.05) reduction in the PCV 
value among HIV positive Patients compared to 
those of the healthy controls. PCV is used to 
screen for anaemia when it is not possible to 
measure haemoglobin concentration accurately. 
And together with haemoglobin, PCV value is 
useful in the calculation of MCHC [43].  
 
The red cell indices: MCV (78.35±6.22fl), MCH 
(24.46±1.92pg) and MCHC (27.95±2.60g/dl) of 
the HIV positive patients were found to be 
significantly lower than those of the healthy 
controls (94.52±13.52fl, 29.77±4.88pg and 
31.56±0.90g/dl, respectively). Red cell indices 
are particularly important for the diagnosis of 
anemia and since the values obtained for the HIV 
positive group are less than the reference range 
(MCV: 80-98fl, MCH: 27-32pg and MCHC: 31.5-
36.0g/dl), it could be said that anaemia exist 
among them, no matter how mild. 
 
It was also observed in this study that the 
Platelet count (245.49±98.88 X103/μL) of the HIV 
groups were lower than the healthy controls 
(253.75±71.76 X103/μL), although not statistically 
significant (P>0.05). This is in accordance with 
the reports of Osime et al. [47] and Raman et al. 
[48]. Thrombocytopenia in HIV infection is due to 
increased platelet destruction by deposition of 
circulating immune complexes on platelets. 
Presence of specific anti-platelet antibodies and 
direct infection of megakaryocytes by HIV are 
also being hypothesized [49].  
 
Furthermore, there was no significant difference 
(P>0.05) between the anti-phospholipid 
antibodies of HIV group on ART (11.44±7.74 
u/ml) and those not on ART (12.00±7.24 u/ml). It 
was also observed that some haematological 
parameters like PLT, PCV, Hb, RBC and red cell 
indices, of the HIV group on ART did not differ 
significantly (P>0.05) from those not on ART. 
These are in agreement with the work of Raman 
et al. [50], who reported no significant differences 
among HIV patients on ART and those not on 
ART with regard to these parameters. However, 
the CD4 count (638.89±119.56 cell/μL), WBC 
(5.38±1.49X103/μL), LYM (51.43±7.99%) and 
GRA (46.30±10.18%) of the HIV group on ART in 
this present study were significant higher than 
those not on ART (465.30±145.92 cell/μL, 
4.55±1.57X103/μL, 42.23±10.96% and 
39.10±7.81%, respectively). This does not agree 
with the work of Raman et al. [50], who reported 
otherwise. 
 
ART is an important intervention in leucopenic 
HIV patients, as it alleviates the cytokine 
disturbances. An increase in CD4 count ranging 
from 154 cell mm-3 to 262 cell mm-3 following 
exposure to ART has been reported by Akele et 
al. [51]. No doubt, elevated CD4 count, have 
been suggested to be a strong indicator of a 
promising life expectancy as the immune cells 
which are the major target of the virus 
appreciated in number. However, if patients 
develop a new leucopenia while taking ART, then 
a drug-induced leucopenia must be considered 
and a change of ART regimen may be necessary 
[46]. 
 
The use of ART therapy is giving rise to a 
substantial change in the clinical spectrum of 
HIV infection, in which an increasing frequency 
of associated autoimmune and lymphomatous 
processes is being described. The persistent 
stimulation of the immune system triggered by 
HIV infection may favour the development of 
autoimmune manifestations [52]. 
 
4. CONCLUSION 
 
The significant elevated aPLs level is present in 
HIV infection; however, the information obtained 
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is not sufficient to indicate the occurrence of anti-
phospholipid syndrome in HIV infection. There 
was no strong relationship between aPLs level 
and indicators of immunohaematological 
abnormalities in HIV infection. This finding is 
plausible and would require further investigation. 
Nevertheless, it is still needful for Clinicians to 
have a high index of suspicion of APS in HIV 
patients who present with a thrombotic episode 
whether they are on antiretroviral therapy or not. 
They should investigate for the presence of 
antiphospholipid antibodies; as early diagnosis 
may influence the course of the HIV/AIDS 
disease. Finally, resources for the detection of 
antiphospholipid antibodies should be made 
readily available in resource-limited settings.  
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